Skip to content
Screener

Innoviva, Inc. INVA EPS (Diluted)

EPS (Diluted) at other companies

Pfizer logo
PfizerPFE
-$0.04-108%
Merck & Co. logo
Merck & Co.MRK
-$0.54-131%
AbbVie logo
AbbVieABBV
$2.03+290%
Insmed logo
InsmedINSM
-$0.06+96.5%
Savara logo
SavaraSVRA
-$0.15-25.0%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$0.96+49.5%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Income tax benefit (expense), net24,600(8,910)(23,368)(16,905)
Net income (loss) and comprehensive income (loss)$(83,420)$63,688$103,175$17,104
Net income (loss) per share:
Basic$(1.14)$1.01$1.40$0.27
Diluted$(1.14)$0.77$1.25$0.24
Shares used to compute net income (loss) per share:
Basic73,42162,86573,78962,787
Diluted73,42184,45284,52984,342

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s EPS (diluted)?
Innoviva, Inc. (INVA) reported EPS (diluted) of -$1.14 in Q2 2026.
How has Innoviva, Inc.'s EPS (diluted) changed year-over-year?
Innoviva, Inc.'s EPS (diluted) decreased by 248.1% year-over-year, from $0.77 to -$1.14.
What is the long-term trend for Innoviva, Inc.'s EPS (diluted)?
Over 3 years (2021 to 2025), Innoviva, Inc.'s EPS (diluted) has grown at a 2.0% compound annual growth rate (CAGR), from $2.88 to $3.06.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Innoviva, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude